Martelli, Alberto Maria
Martelli, Alberto Maria
Istituto di Genetica Molecolare "Luigi Luca Cavalli Sforza"
The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH
2024 Cervello, Melchiorre; Augello, Giuseppa; Cocco, Lucio; Ratti, Stefano; Follo, Matilde Y.; Martelli, Alberto M.; Cusimano, Antonella; Montalto, Giuseppe; Mccubrey, James A.
Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy
2016 Candido, S; Abrams, Sl; Steelman, Ls; Lertpiriyapong, K; Fitzgerald, Tl; Martelli, Am; Cocco, L; Montalto, G; Cervello, M; Polesel, J; Libra, M; Mccubrey, Ja
Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment
2013 Chappell, Wh; Abrams, Sl; Stadelman, Km; Lahair, Mm; Franklin, Ra; Cocco, L; Evangelisti, C; Chiarini, F; Martelli, Am; Steelman, Ls; Mccubrey, Ja
The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy
2013 Simioni, C; Martelli, Am; Cani, A; Cetinatalay, R; Mccubrey, Ja; Capitani, S; Neri, Lm
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients.
2012 Follo, My; Mongiorgi, S; Clissa, C; Paolini, S; Martinelli, G; Martelli, Am; Fioravanti, G; Manzoli, L; Finelli, C; Cocco, L
Activity of the selective I?B kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a.
2012 Buontempo F; Chiarini F; Bressanin D; Tabellini G; Melchionda F; Pession A; Fini M; Neri LM; McCubrey JA; Martelli AM.
AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications.
2012 Grimaldi C; Chiarini F; Tabellini G; Ricci F; Tazzari PL; Battistelli M; Falcieri E; Bortul R; Melchionda F; Iacobucci I; Pagliaro P; Martinelli G; Pession A; Barata JT; McCubrey JA; Martelli AM.
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.
2012 Simioni, C; Neri, Lm; Tabellini, G; Ricci, F; Bressanin, D; Chiarini, F; Evangelisti, C; Cani, A; Tazzari, Pl; Melchionda, F; Pagliaro, P; Pession, A; Mccubrey, Ja; Capitani, S; Martelli, Am
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine.
2012 Chappell, Wh; Abrams, Sl; Franklin, Ra; Lahair, Mm; Montalto, G; Cervello, M; Martelli, Am; Nicoletti, F; Candido, S; Libra, M; Polesel, J; Talamini, R; Milella, M; Tafuri, A; Steelman, Ls; Mccubrey, Ja
Effects of ectopic expression of NGAL on doxorubicin sensitivity
2012 Chappell, Wh; Abrams, Sl; Montalto, G; Cervello, M; Martelli, Am; Candido, S; Libra, M; Polesel, J; Talamini, R; Arlinghaus, R; Steelman, Ls; Mccubrey, Ja
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels.
2012 Bressanin, D; Evangelisti, C; Ricci, F; Tabellini, G; Chiarini, F; Tazzari, Pl; Melchionda, F; Buontempo, F; Pagliaro, P; Pession, A; Mccubrey, Ja; Martelli, Am
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance.
2012 Mccubrey, Ja; Steelman, Ls; Chappell, Wh; Abrams, Sl; Franklin, Ra; Montalto, G; Cervello, M; Libra, M; Candido, S; Malaponte, G; Mazzarino, Mc; Fagone, P; Nicoletti, F; Bäsecke, J; Mijatovic, S; Maksimovicivanic, D; Milella, M; Tafuri, A; Chiarini, F; Evangelisti, C; Cocco, L; Martelli, Am
Targeting the cancer initiating cell: The ultimate target for cancer therapy
2012 Mccubrey, Ja; Steelman, Ls; Abrams, Sl; Misaghian, N; Chappell, Wh; Basecke, J; Nicoletti, F; Libra, M; Ligresti, G; Stivala, F; Maksimovicivanic, D; Mijatovic, S; Montalto, G; Cervello, M; Laidler, P; Bonati, A; Evangelisti, C; Cocco, L; Martelli, Am
The emerging multiple roles of nuclear Akt.
2012 Martelli AM; Tabellini G; Bressanin D; Ognibene A; Goto K; Cocco L; Evangelisti C.
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.
2012 Martelli AM; Chiarini F; Evangelisti C; Cappellini A; Buontempo F; Bressanin D; Fini M; McCubrey JA.
Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity.
2011 Steelman, Ls; Martelli, Am; Nicoletti, F; Mccubrey, Ja
Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.
2011 Steelman LS; Navolanic P; Chappell WH; Abrams SL; Wong EW; Martelli AM; Cocco L; Stivala F; Libra M; Nicoletti F; Drobot LB; Franklin RA; McCubrey JA.
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy
2011 Sokolosky, Ml; Stadelman, Km; Chappell, Wh; Abrams, Sl; Martelli, Am; Stivala, F; Libra, M; Nicoletti, F; Drobot, Lb; Franklin, Ra; Steelman, Ls; Mccubrey, Ja
Multiple forms of PKR present in the nuclei of acute leukemia cells represent an active kinase that is responsive to stress.
2011 Blalock, Wl; Bavelloni, A; Piazzi, M; Tagliavini, F; Faenza, I; Martelli, Am; Follo, My; Cocco, L
Nuclear phosphoinositides and their roles in cell biology and disease.
2011 Martelli, Am; Ognibene, A; Buontempo, F; Fini, M; Bressanin, D; Goto, K; Mccubrey, Ja; Cocco, L; Evangelisti, C
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| The potential of the nutraceutical berberine in the treatment of hepatocellular carcinoma and other liver diseases such as NAFLD and NASH | 1-gen-2024 | Cervello, Melchiorre; Augello, Giuseppa; Cocco, Lucio; Ratti, Stefano; Follo, Matilde Y.; Martelli, Alberto M.; Cusimano, Antonella; Montalto, Giuseppe; Mccubrey, James A. | |
| Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy | 1-gen-2016 | Candido, S; Abrams, Sl; Steelman, Ls; Lertpiriyapong, K; Fitzgerald, Tl; Martelli, Am; Cocco, L; Montalto, G; Cervello, M; Polesel, J; Libra, M; Mccubrey, Ja | |
| Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment | 1-gen-2013 | Chappell, Wh; Abrams, Sl; Stadelman, Km; Lahair, Mm; Franklin, Ra; Cocco, L; Evangelisti, C; Chiarini, F; Martelli, Am; Steelman, Ls; Mccubrey, Ja | |
| The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy | 1-gen-2013 | Simioni, C; Martelli, Am; Cani, A; Cetinatalay, R; Mccubrey, Ja; Capitani, S; Neri, Lm | |
| Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients. | 1-gen-2012 | Follo, My; Mongiorgi, S; Clissa, C; Paolini, S; Martinelli, G; Martelli, Am; Fioravanti, G; Manzoli, L; Finelli, C; Cocco, L | |
| Activity of the selective I?B kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a. | 1-gen-2012 | Buontempo F; Chiarini F; Bressanin D; Tabellini G; Melchionda F; Pession A; Fini M; Neri LM; McCubrey JA; Martelli AM. | |
| AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. | 1-gen-2012 | Grimaldi C; Chiarini F; Tabellini G; Ricci F; Tazzari PL; Battistelli M; Falcieri E; Bortul R; Melchionda F; Iacobucci I; Pagliaro P; Martinelli G; Pession A; Barata JT; McCubrey JA; Martelli AM. | |
| Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. | 1-gen-2012 | Simioni, C; Neri, Lm; Tabellini, G; Ricci, F; Bressanin, D; Chiarini, F; Evangelisti, C; Cani, A; Tazzari, Pl; Melchionda, F; Pagliaro, P; Pession, A; Mccubrey, Ja; Capitani, S; Martelli, Am | |
| Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. | 1-gen-2012 | Chappell, Wh; Abrams, Sl; Franklin, Ra; Lahair, Mm; Montalto, G; Cervello, M; Martelli, Am; Nicoletti, F; Candido, S; Libra, M; Polesel, J; Talamini, R; Milella, M; Tafuri, A; Steelman, Ls; Mccubrey, Ja | |
| Effects of ectopic expression of NGAL on doxorubicin sensitivity | 1-gen-2012 | Chappell, Wh; Abrams, Sl; Montalto, G; Cervello, M; Martelli, Am; Candido, S; Libra, M; Polesel, J; Talamini, R; Arlinghaus, R; Steelman, Ls; Mccubrey, Ja | |
| Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels. | 1-gen-2012 | Bressanin, D; Evangelisti, C; Ricci, F; Tabellini, G; Chiarini, F; Tazzari, Pl; Melchionda, F; Buontempo, F; Pagliaro, P; Pession, A; Mccubrey, Ja; Martelli, Am | |
| Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. | 1-gen-2012 | Mccubrey, Ja; Steelman, Ls; Chappell, Wh; Abrams, Sl; Franklin, Ra; Montalto, G; Cervello, M; Libra, M; Candido, S; Malaponte, G; Mazzarino, Mc; Fagone, P; Nicoletti, F; Bäsecke, J; Mijatovic, S; Maksimovicivanic, D; Milella, M; Tafuri, A; Chiarini, F; Evangelisti, C; Cocco, L; Martelli, Am | |
| Targeting the cancer initiating cell: The ultimate target for cancer therapy | 1-gen-2012 | Mccubrey, Ja; Steelman, Ls; Abrams, Sl; Misaghian, N; Chappell, Wh; Basecke, J; Nicoletti, F; Libra, M; Ligresti, G; Stivala, F; Maksimovicivanic, D; Mijatovic, S; Montalto, G; Cervello, M; Laidler, P; Bonati, A; Evangelisti, C; Cocco, L; Martelli, Am | |
| The emerging multiple roles of nuclear Akt. | 1-gen-2012 | Martelli AM; Tabellini G; Bressanin D; Ognibene A; Goto K; Cocco L; Evangelisti C. | |
| Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. | 1-gen-2012 | Martelli AM; Chiarini F; Evangelisti C; Cappellini A; Buontempo F; Bressanin D; Fini M; McCubrey JA. | |
| Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity. | 1-gen-2011 | Steelman, Ls; Martelli, Am; Nicoletti, F; Mccubrey, Ja | |
| Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. | 1-gen-2011 | Steelman LS; Navolanic P; Chappell WH; Abrams SL; Wong EW; Martelli AM; Cocco L; Stivala F; Libra M; Nicoletti F; Drobot LB; Franklin RA; McCubrey JA. | |
| Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy | 1-gen-2011 | Sokolosky, Ml; Stadelman, Km; Chappell, Wh; Abrams, Sl; Martelli, Am; Stivala, F; Libra, M; Nicoletti, F; Drobot, Lb; Franklin, Ra; Steelman, Ls; Mccubrey, Ja | |
| Multiple forms of PKR present in the nuclei of acute leukemia cells represent an active kinase that is responsive to stress. | 1-gen-2011 | Blalock, Wl; Bavelloni, A; Piazzi, M; Tagliavini, F; Faenza, I; Martelli, Am; Follo, My; Cocco, L | |
| Nuclear phosphoinositides and their roles in cell biology and disease. | 1-gen-2011 | Martelli, Am; Ognibene, A; Buontempo, F; Fini, M; Bressanin, D; Goto, K; Mccubrey, Ja; Cocco, L; Evangelisti, C |